• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌。

Hepatocellular Carcinoma.

机构信息

Central Virginia Veterans Affairs Medical Center, 1201 Broad Rock Blvd (111N), Richmond, VA 23249, USA.

Central Virginia Veterans Affairs Medical Center, 1201 Broad Rock Blvd (111N), Richmond, VA 23249, USA.

出版信息

Crit Care Nurs Clin North Am. 2022 Sep;34(3):289-301. doi: 10.1016/j.cnc.2022.04.004. Epub 2022 Jul 20.

DOI:10.1016/j.cnc.2022.04.004
PMID:36049848
Abstract

Hepatocellular carcinoma (HCC) is a primary liver malignancy commonly encountered in the setting of chronic liver disease and cirrhosis. Survival in HCC is determined by the ABCs: (A) anatomic stage; (B) biologic grade; and (C) cirrhosis severity. Improvement of imaging techniques permits clinicians to accurately diagnose HCC without biopsy confirmation. Advances in surgical and therapeutic options have improved treatment response and survival. Surgical resection, liver transplant, and thermal ablation in selected patients can potentially cure HCC. Noncurative approaches including intraarterial, radiation, and systemic therapies aim to palliate or slow the progression of disease. Management of HCC is complex, and the choice of treatment approach is enhanced by multidisciplinary consensus, including a liver transplant center.

摘要

肝细胞癌 (HCC) 是一种常见于慢性肝病和肝硬化背景下的原发性肝脏恶性肿瘤。HCC 的生存取决于 ABCs:(A) 解剖分期;(B) 生物学分级;和 (C) 肝硬化严重程度。影像学技术的改进使得临床医生无需活检即可准确诊断 HCC。手术和治疗选择的进步改善了治疗反应和生存。在选定的患者中,手术切除、肝移植和热消融术可能治愈 HCC。非治愈方法包括动脉内、放射和全身治疗,旨在缓解或减缓疾病进展。HCC 的管理很复杂,通过多学科共识(包括肝移植中心)可以增强治疗方法的选择。

相似文献

1
Hepatocellular Carcinoma.肝细胞癌。
Crit Care Nurs Clin North Am. 2022 Sep;34(3):289-301. doi: 10.1016/j.cnc.2022.04.004. Epub 2022 Jul 20.
2
[Hepatocellular carcinoma].肝细胞癌
Ther Umsch. 2011 Apr;68(4):213-7. doi: 10.1024/0040-5930/a000153.
3
Hepatocellular carcinoma: a review of the surgical approaches to management.肝细胞癌:治疗的手术方法综述
Mo Med. 2011 May-Jun;108(3):195-8.
4
[Treatment of hepatocellular carcinoma in the cirrhotic liver].[肝硬化肝脏中肝细胞癌的治疗]
J Chir (Paris). 2004 Mar;141(2):71-83. doi: 10.1016/s0021-7697(04)95574-3.
5
Surgical resection and liver transplantation for hepatocellular carcinoma.手术切除和肝移植治疗肝细胞癌。
Clin Liver Dis. 2015 May;19(2):381-99. doi: 10.1016/j.cld.2015.01.007. Epub 2015 Mar 2.
6
Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update.肝硬化肝细胞癌的多模态治疗:最新进展。
World J Gastroenterol. 2013 Nov 14;19(42):7316-26. doi: 10.3748/wjg.v19.i42.7316.
7
Recent advances in the treatment of hepatocellular carcinoma.肝细胞癌治疗的最新进展。
Curr Opin Gastroenterol. 2013 May;29(3):285-92. doi: 10.1097/MOG.0b013e32835ff1cf.
8
Management of HCC.肝癌的治疗。
J Hepatol. 2012;56 Suppl 1:S75-87. doi: 10.1016/S0168-8278(12)60009-9.
9
New concepts in the treatment of hepatocellular carcinoma.肝细胞癌治疗的新概念。
United European Gastroenterol J. 2022 Sep;10(7):765-774. doi: 10.1002/ueg2.12286. Epub 2022 Aug 16.
10
Evaluation and management of hepatocellular carcinoma.肝细胞癌的评估与管理
Clin Liver Dis. 2015 Feb;19(1):23-43. doi: 10.1016/j.cld.2014.09.002. Epub 2014 Oct 30.

引用本文的文献

1
TUG1 targeting enhances anticancer immunity thereby facilitating lenvatinib efficacy in hepatocellular carcinoma.靶向TUG1可增强抗癌免疫力,从而提高乐伐替尼在肝细胞癌中的疗效。
Genes Immun. 2025 Sep 15. doi: 10.1038/s41435-025-00358-y.
2
A migrasome-related lncRNA signature predicts prognosis and immune response in hepatocellular carcinoma: Implications for biomarker discovery and therapeutic targeting.一种与迁移小体相关的长链非编码RNA特征可预测肝细胞癌的预后和免疫反应:对生物标志物发现和治疗靶点的意义。
Front Pharmacol. 2025 Aug 6;16:1581122. doi: 10.3389/fphar.2025.1581122. eCollection 2025.
3
Preliminary analysis of the diagnostic value and mechanism of action of TGFbI and S100A4 in hepatocellular carcinoma.
转化生长因子β1(TGFbI)和S100A4在肝细胞癌中的诊断价值及作用机制的初步分析
J Med Biochem. 2025 Jun 13;44(3):400-411. doi: 10.5937/jomb0-54550.
4
Impact of Multidisciplinary Continuity of Care on Postoperative Outcomes in Liver Cancer Surgical Patients.多学科连续性护理对肝癌手术患者术后结局的影响
J Multidiscip Healthc. 2025 Aug 6;18:4749-4759. doi: 10.2147/JMDH.S527399. eCollection 2025.
5
Molecular Subtyping of Hepatocellular Carcinoma via Lysosome-Related Genes for Prognosis and Therapy Prediction.通过溶酶体相关基因对肝细胞癌进行分子分型以预测预后和指导治疗
Int J Gen Med. 2025 Jul 16;18:3933-3950. doi: 10.2147/IJGM.S490019. eCollection 2025.
6
Medicinal Plant-Derived Exosome-Like Nanovesicles as Regulatory Mediators in Microenvironment for Disease Treatment.药用植物来源的类外泌体纳米囊泡作为疾病治疗微环境中的调节介质
Int J Nanomedicine. 2025 Jun 30;20:8451-8479. doi: 10.2147/IJN.S526287. eCollection 2025.
7
Evaluation of the efficacy of laparoscopic hepatolobectomy for primary liver cancer with early combined enteral and parenteral nutritional support.早期肠内与肠外营养支持联合应用对腹腔镜肝叶切除术治疗原发性肝癌疗效的评估
Discov Oncol. 2025 Jun 12;16(1):1079. doi: 10.1007/s12672-025-02851-2.
8
Transcription Factor TCF12 Activates the Transcription Level of SLC38A1 to Promote the Development of Hepatocellular Carcinoma.转录因子TCF12激活SLC38A1的转录水平以促进肝细胞癌的发展。
Appl Biochem Biotechnol. 2025 Jun 6. doi: 10.1007/s12010-025-05263-8.
9
The impact of ultrasound contrast-enhanced fusion virtual navigation technology-guided microwave ablation (MWA) and standard MWA on the local tumor progression of hepatocellular carcinoma with unclear ultrasound images.超声造影增强融合虚拟导航技术引导下的微波消融(MWA)与标准MWA对超声图像不清晰的肝细胞癌局部肿瘤进展的影响
Eur J Med Res. 2025 Jun 4;30(1):451. doi: 10.1186/s40001-025-02608-1.
10
A reliable prognostic model for hepatocellular carcinoma using neutrophil extracellular traps and immune related genes.一种利用中性粒细胞胞外诱捕网和免疫相关基因构建的肝细胞癌可靠预后模型。
Sci Rep. 2025 Jun 3;15(1):19390. doi: 10.1038/s41598-025-01335-1.